Table 2.

Risk of breast cancer in atypical hyperplasia by ER expression levels and type of atypia

All SubjectsADH1ALH1
NObsExpSIR (95% CI)2P-valueNObsExpSIR (95% CI)2P-valueNObsExpSIR (95% CI)2P-value
Percent staining0.970.390.80
0–1961133.24.01 (2.33–6.90)710.42.29 (0.32–16.3)51112.64.23 (2.34–7.64
20–395492.63.43 (1.79–6.59)1330.74.60 (1.48–14.3)3851.82.85 (1.18–6.84)
40–5953102.83.53 (1.90–6.56)1100.6NA3571.93.69 (1.76–7.73)
60–7953122.74.39 (2.49–7.74)3351.73.01 (1.25–7.24)1530.83.54 (1.14–11.0)
80+2551.53.27 (1.36–7.84)2351.43.62 (1.51–8.71)200.2NA
Intensity of staining0.250.010.71
0–9999204.84.21 (2.71–6.52)1110.52.03 (0.29–14.4)84164.13.93 (2.41–6.41)
100–11970173.74.54 (2.82–7.30)1961.06.12 (2.75–13.6)4172.13.26 (1.55–6.84)
120–1393842.31.71 (0.64–4.56)2101.3NA1430.93.45 (1.11–10.7)
140+3982.13.76 (1.88–7.52)3671.93.69 (1.76–7.74)200.2NA
Product of percent, intensity0.970.660.77
0–1968163.74.38 (2.68–7.14)1010.61.66 (0.23–11.8)54132.84.70 (2.73–8.09)
20–394161.93.24 (1.45–7.20)620.28.84 (2.21–35.3)3341.52.69 (1l01–7.16)
40–594382.23.66 (1.83–7.31)1110.51.90 (0.27–13.5)2841.52.59 (0.97–6.91)
60–792751.53.34 (1.39–8.02)710.42.44 (0.34–17.3)1530.83.92 (1.26–12.1)
80+67143.83.72 (2.20–6.27)5392.93.07 (1.60–5.91)1120.72.89 (0.72–11.6)

N, number of subjects; Obs, observed number of breast cancer events; Exp, expected number of breast cancer events; SIR, standardized incidence ratio; CI, confidence interval

  • 1 Subjects with both ALH and ADH excluded from histology specific analysis

  • 2 SIRs and corresponding 95% confidence intervals compare the observed number of breast cancer events to those expected based on incidence rates from Iowa SEER data. Analyses account for the effects of age and calendar period. P-values test for heterogeneity in the SIRs across levels of ER expression.